Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease

Novo NordiskEmbark Biotech ApS and Novo Nordisk A/S have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure.

The research platform of Embark Biotech, a recent spin-out from Center for Basic Metabolic Research at University of Copenhagen, builds on novel and unique insights into receptors that stimulate energy expenditure without triggering the sympathetic nervous system (the 'fight-or-flight' response). The aim of the collaboration is to develop novel drug candidates that help people with obesity lose weight by burning off excess energy instead of storing it as fat. The potential addition of energy expenditure drugs would make a meaningful difference in the treatment of obesity.

The work behind the research platform and the spin-out of Embark Biotech has been supported by Novo Seeds and the Novo Nordisk Foundation since 2016.

"The present project builds on the frontline insight into energy expenditure of the group of Zach Gerhart-Hines, who we recruited from the US to Center for Basic Metabolic Research just few years ago. Zach's group has fully exploited the special knowledge we have in cell surface receptor pharmacology to generate several innovative drug discovery projects, and we see the research collaboration with Novo Nordisk, a global leader within obesity care, as the optimal way of developing the technology to ultimately benefit the patients," says Thue W. Schwartz, professor at Center for Basic Metabolic Research and co-founder of Embark.

As part of the collaboration agreement, Embark will receive research support for activities conducted in the collaboration, and Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialise products discovered in the collaboration.

"We are excited to get started on this project which aims at developing next- generation anti-obesity therapies" says Marcus Schindler, senior vice president of Global Drug Discovery in Novo Nordisk. "There is a huge unmet medical need for treatment of obesity. While more than 650 million people are currently living with obesity[1], it is rarely acknowledged, diagnosed or treated as a serious chronic and complex disease. We believe that Novo Nordisk and Embark together have both the capability and capacity to explore this new mechanism of action."

About Embark

Embark Biotech ApS is a spin-out platform biotech company from University of Copenhagen, dedicated to deciphering the therapeutic potential of energy expenditure. The academic founders include Professor Thue W Schwartz, Associate Professor Zach Gerhart-Hines, Postdoc Jakob Bondo Hansen and CEO, Casper Tind Hansen.

The research platform and spin-out of Embark Biotech has been supported by exploratory pre-seed and pre-seed grants from Novo Seeds administered on behalf of the Novo Nordisk Foundation and by starting grants from the European Research Council (ERC) and the Danish Council for Independent Research, as well as proof-of-concept grants from the European Research Council and the University of Copenhagen Tech Transfer Office.

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries and markets its products in more than 170 countries.

1. NCD Risk Factor Collaboration (NCD-RisC). Lancet 2017:390;2627-42

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...